Cardiovascular Disease, Coronary Disease
Conditions
Keywords
Rehabilitation, Coronary artery disease, Patient Education, Randomized Controlled Trial, Protocol
Brief summary
The purpose of this trial are to pragmatically investigate whether participation in a comprehensive CR (i.e., exercise with education) program in a Latin American MIC results in better functional capacity, cardiovascular risk factor control, health behavior, disease-related knowledge, depressive symptoms and lower mortality when compared exercise only CR or wait list control.
Detailed description
The design is a single-blinded, single-site pragmatic superiority RCT with 3 parallel arms: comprehensive CR (education and exercise) versus exercise-based CR (no education, as delivered in Brazil) versus wait list control (i.e., no CR). Patient assessments will be undertaken pre-randomization and again at 6 and 12 months later (in accordance with the end of CR). Mortality will be ascertained at 6 months and 1 year post-recruitment. The main program is 6 months in duration, with 36 1-hour exercise sessions offered at the following frequencies: 1. participants come to CR for 12 sessions, 3x a week (total of 4 weeks of intervention). 2. participants come to CR for 8 sessions, 2x a week (total of 4 weeks of intervention). 3. participants come to CR for 12 sessions, 1x a week (total of 12 weeks of intervention). Each participant will receive an individualized exercise prescription based on a grade exercise stress test. Participants will be exercising between 50 and 80% of heart rate reserve. In all stages patients will be requested to exercise in their community other days of the week, to accumulate 30 or more minutes of physical activity at a moderate to vigorous-intensity 5 or more days per week, as recommended in the guidelines. In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration. More specifically, the education component consists of: * weekly group education sessions, which are strategically mapped based on patients' information needs and sequenced to support the program learning outcomes. Education sessions are delivered by a health educator team. See table 1 for the CR program schedule, including educational topics (e.g.. diet, medication and exercise). * A comprehensive education workbook to accompany the sessions, containing 20 chapters. The empirically-validated English version has been translated and culturally-adapted to Brazilian-Portuguese. Clinicians and patients have reviewed the material, and a plain language and clear design review was completed in preparation for this trial. The standard of care for Brazilian adults with CVD does not include access to CR for all patients, given the gross lack of capacity. All participants will have follow-up appointments with their physician as deemed medically appropriate. Consistent with CONSORT guidelines, usual care will be described in detail for each participant (e.g., number of health visits - both inpatient and outpatient, other treatments). The number of patients approached and date will be recorded, as well as the reasons for inclusion/exclusion. With informed written consent from the patient and CR clearance from the physician, potentially eligible participants will be scheduled to come on-site to complete pre-test assessments. Participants will be asked to complete a sociodemographic questionnaire, to establish the generalizability of the sample, among other surveys. Clinical information will be extracted from participants' charts. Eligible participants will be randomized to one of the 3 groups. The randomization sequence was generated using the random.org website in random blocks of 4, with a 1:1:1 allocation ratio. To ensure allocation concealment, the local principal investigator has the allocation sequence in a password-protected file, and will only provide randomization information to the student once it is confirmed the participant is eligible. Due to the nature of the intervention, participants and the doctoral student cannot be blind to treatment allocation. The primary outcome of functional capacity will be assessed again at 6 months. All other post-test assessments will be undertaken 6 months post-randomization. Mortality will be ascertained from hospital charts and family phone call at 6 months and 1-year. With regard to the baseline and 6 months assessments, participants will be invited to come to the study center to: 1. undertake the shuttle walk test as the indicator of functional capacity, 2. undertake assessments of secondary outcomes including a blood draw for lipids, and 3. complete surveys related to tertiary outcomes. A master's student blinded to random allocation will undertake post-test assessments, outcome ascertainment and data entry. To minimize loss to follow-up, investigators will send mail and telephone reminders for patients to come on-site for these assessments, based on the Dillman method. Measures Participants will be asked to complete a sociodemographic questionnaire. Clinical characteristics will be extracted from the medical charts, including sex, age, risk factors, cardiac history, cardiac test results, comorbidities and medications. These are based on the Canadian Cardiovascular Society core element and demographic data definitions. CR session attendance will be extracted from program charts at post-test for participants randomized to the CR arms.
Interventions
In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
The main program is 6 months in duration, with 36 1-hour exercise sessions.
No cardiac rehabilitation.
Sponsors
Study design
Eligibility
Inclusion criteria
* patients older than 18 years old * patients living in the Belo Horizonte area
Exclusion criteria
* any comorbid physical or serious mental condition which would interfere with the ability to exercise according to CR clinical practice guidelines (i.e., heart failure with ejection fraction less than 45%, complex ventricular dysrhythmia, advanced dementia, leg amputation, advanced cancer, disabling stroke, Parkinson's or substance dependence), and * any visual or cognitive condition which would preclude the participant from completing the questionnaires.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test | Functional capacity measured by walked distance in the ISWT at 6 months | The Incremental Shuttle Walk Test (ISWT). The ISWT consists of an incremental, walking test where participants are required to walk up and down a 10-meter course. The speed of walking, which is increased by a small increment every minute (0.17 ms-l), is externally paced and controlled by audio signals played from a tape recorder19. There are 12 levels in total, beginning with 0.5 ms-1, and each level lasts for one minute. At the end of each minute, exercise heart rate (HR) and rating of perceived exertion (RPE) scores will be recorded. For this test, the higher the number of meters, the higher the functional capacity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk Factors Measurement of Systolic Blood Pressure | Systolic blood pressure measured at 6 months | Blood pressure was assessed using the validated 7670-06 mobile stand (Welch Allyn Inc., Skaneateles Falls, NY, USA). Mean systolic blood pressure value was recorded, and hypertension was considered where values exceed 140/90 mmHg and/or participant was taking a blood pressure-lowering medication |
| Risk Factors Measurement of Waist Circumference. | Waist circumference measured at 6 months | Waist circumference was assessed at the superior border of the iliac crest. Values greater than 102 cm in men and 88 cm in women were considered indicative of central obesity. |
| Risk Factors Measurement of Fasting Blood Glucose Values | Glycaemia measured at 6 months | Fasting blood glucose values were extracted from center charts. Dysglycemia was considered present where fasting blood glucose exceeded 126 mg/dl and/or participant was taking a glucose-lowering medication |
| Risk Factors Measurement of Total Cholesterol Values. | Cholesterol measured at 6 months. | Total cholesterol values were extracted from center charts and dyslipidemia was considered present where total cholesterol values exceeded 240 mg/dl and/or participant was on a lipid-lowering agent. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Heart-health Behaviors | Measured at 6 months. | Assessed by questionnaires. |
Countries
Brazil
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Comprehensive CR education and exercise-based cardiac rehabilitation
comprehensive CR: In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions) | 37 |
| Exercise-based CR Exercise-based cardiac rehabilitation
exercise-based CR: The main program is 6 months in duration, with 36 1-hour exercise sessions. | 39 |
| Wait List Control no cardiac rehabilitation
wait list control: No cardiac rehabilitation. | 39 |
| Total | 115 |
Baseline characteristics
| Characteristic | Comprehensive CR | Exercise-based CR | Wait List Control | Total |
|---|---|---|---|---|
| Age, Continuous | 60.7 years STANDARD_DEVIATION 8.8 | 59.0 years STANDARD_DEVIATION 9.9 | 58.7 years STANDARD_DEVIATION 9.6 | 59.5 years STANDARD_DEVIATION 9.4 |
| Low Education | 21 Participants | 33 Participants | 28 Participants | 82 Participants |
| Low Monthly income | 31 Participants | 34 Participants | 35 Participants | 100 Participants |
| Marital status - Married | 20 Participants | 27 Participants | 27 Participants | 74 Participants |
| Race and Ethnicity Not Collected | — | — | — | 0 Participants |
| Sex: Female, Male Female | 10 Participants | 11 Participants | 12 Participants | 33 Participants |
| Sex: Female, Male Male | 27 Participants | 28 Participants | 27 Participants | 82 Participants |
| Work status - employed | 15 Participants | 14 Participants | 17 Participants | 46 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 37 | 0 / 39 | 1 / 39 |
| other Total, other adverse events | 0 / 37 | 0 / 39 | 0 / 39 |
| serious Total, serious adverse events | 0 / 37 | 0 / 39 | 0 / 39 |
Outcome results
Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test
The Incremental Shuttle Walk Test (ISWT). The ISWT consists of an incremental, walking test where participants are required to walk up and down a 10-meter course. The speed of walking, which is increased by a small increment every minute (0.17 ms-l), is externally paced and controlled by audio signals played from a tape recorder19. There are 12 levels in total, beginning with 0.5 ms-1, and each level lasts for one minute. At the end of each minute, exercise heart rate (HR) and rating of perceived exertion (RPE) scores will be recorded. For this test, the higher the number of meters, the higher the functional capacity.
Time frame: Functional capacity measured by walked distance in the ISWT at 6 months
Population: The analyzed population was based on the threshold sessions: a minimum of 24 exercise sessions and 16 education classes. The presented results considered the Per Protocol analysis, explaining the different numbers in the flow diagram and the analyzed numbers.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive CR | Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test | 488.1 meters | Standard Deviation 106.3 |
| Exercise-based CR | Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test | 464.8 meters | Standard Deviation 121.6 |
| Wait List Control | Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test | 394.0 meters | Standard Deviation 171.9 |
Risk Factors Measurement of Fasting Blood Glucose Values
Fasting blood glucose values were extracted from center charts. Dysglycemia was considered present where fasting blood glucose exceeded 126 mg/dl and/or participant was taking a glucose-lowering medication
Time frame: Glycaemia measured at 6 months
Population: The analyzed population was based on the threshold sessions: a minimum of 24 exercise sessions and 16 education classes. The presented results considered the Per Protocol analysis, explaining the different numbers in the flow diagram and the analyzed numbers. Sample size reduced because difficult to obtain the results in a reasonable time frame.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive CR | Risk Factors Measurement of Fasting Blood Glucose Values | 99.8 mg/dl | Standard Deviation 20.9 |
| Exercise-based CR | Risk Factors Measurement of Fasting Blood Glucose Values | 98.8 mg/dl | Standard Deviation 27.3 |
| Wait List Control | Risk Factors Measurement of Fasting Blood Glucose Values | 94.2 mg/dl | Standard Deviation 10.4 |
Risk Factors Measurement of Systolic Blood Pressure
Blood pressure was assessed using the validated 7670-06 mobile stand (Welch Allyn Inc., Skaneateles Falls, NY, USA). Mean systolic blood pressure value was recorded, and hypertension was considered where values exceed 140/90 mmHg and/or participant was taking a blood pressure-lowering medication
Time frame: Systolic blood pressure measured at 6 months
Population: The analyzed population was based on the threshold sessions: a minimum of 24 exercise sessions and 16 education classes. The presented results considered the Per Protocol analysis, explaining the different numbers in the flow diagram and the analyzed numbers.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive CR | Risk Factors Measurement of Systolic Blood Pressure | 114.6 mmHg | Standard Deviation 19.2 |
| Exercise-based CR | Risk Factors Measurement of Systolic Blood Pressure | 114.4 mmHg | Standard Deviation 16.3 |
| Wait List Control | Risk Factors Measurement of Systolic Blood Pressure | 120.0 mmHg | Standard Deviation 18.4 |
Risk Factors Measurement of Total Cholesterol Values.
Total cholesterol values were extracted from center charts and dyslipidemia was considered present where total cholesterol values exceeded 240 mg/dl and/or participant was on a lipid-lowering agent.
Time frame: Cholesterol measured at 6 months.
Population: The analyzed population was based on the threshold sessions: a minimum of 24 exercise sessions and 16 education classes. The presented results considered the Per Protocol analysis, explaining the different numbers in the flow diagram and the analyzed numbers. Sample size reduced because difficult to obtain the results in a reasonable time frame.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive CR | Risk Factors Measurement of Total Cholesterol Values. | 150.6 mg/dl | Standard Deviation 25.4 |
| Exercise-based CR | Risk Factors Measurement of Total Cholesterol Values. | 169.3 mg/dl | Standard Deviation 51 |
| Wait List Control | Risk Factors Measurement of Total Cholesterol Values. | 153.1 mg/dl | Standard Deviation 29.8 |
Risk Factors Measurement of Waist Circumference.
Waist circumference was assessed at the superior border of the iliac crest. Values greater than 102 cm in men and 88 cm in women were considered indicative of central obesity.
Time frame: Waist circumference measured at 6 months
Population: The analyzed population was based on the threshold sessions: a minimum of 24 exercise sessions and 16 education classes. The presented results considered the Per Protocol analysis, explaining the different numbers in the flow diagram and the analyzed numbers.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive CR | Risk Factors Measurement of Waist Circumference. | 95.5 centimeters | Standard Deviation 13.4 |
| Exercise-based CR | Risk Factors Measurement of Waist Circumference. | 93.0 centimeters | Standard Deviation 10 |
| Wait List Control | Risk Factors Measurement of Waist Circumference. | 94.9 centimeters | Standard Deviation 9.4 |
Heart-health Behaviors
Assessed by questionnaires.
Time frame: Measured at 6 months.